Business Wire

Sterlite Tech Strengthens Global Leadership Team

Del

Sterlite Tech [BSE:532374, NSE:STRTECH], an end-to-end global technology leader in smarter digital networks, has strengthened its global leadership team with the appointment of Steve Bullock in North America and Richard Eichhorn in EMEA to lead and strengthen its business initiatives in these geographies.

Sterlite Tech engages in six continents and more than 100 countries, with a smarter digital networks focused business panning across optical communication products, system integration services and OSS/BSS software. The company has a unique silicon-to-software capability that enables it to design, build and manage smarter data networks for key customers such as global service providers, smart cities, rural broadband and large enterprises.

With 146 patents and industry recognitions for customer engagement and product excellence, Sterlite Tech has a growing presence in the North American and EMEA markets. Steve will be responsible for enabling Sterlite Tech’s engagement with leading telecom, internet and CATV service providers in North America. Steve brings 25 years of experience in telecom and technology sectors, with companies such as IBM, General Instrument, Motorola and Google. His recent association was with TE Connectivity as VP-Global Go-to-Market for Broadband Network Solution Division. He has completed his Bachelor’s in European Economics from Nantes University, France.

Richard will be responsible to strengthen Sterlite Tech’s presence in Europe, Middle East and Africa. With 28 years of experience in ICT, structured cabling, datacom, telecom cables, network equipment, hardware and services, Richard has been associated with companies such as Reichle & De-Massari AG, Nexans Cabling Solutions, Anixter and Alcatel Connect. His last assignment was with Wesco International Inc as Sales Director – EMEA. He has completed his higher technical education in Energy and Telematica and NIMA Sales A and Sales B courses from ISW, Netherlands.

Highlighting the appointments, Ankit Agarwal, Head – Global Sales (Telecom Products), Sterlite Tech, said, “With many governments including the broadband agenda in their policy-level initiatives, we are witnessing increasing investments in smarter network technologies. Both Steve and Richard have vast experience in the Americas, Europe and Asia, which will enable deeper understanding of customers’ network requirements.”

Asserting Sterlite Tech’s expanding global presence and capacities, Dr. Anand Agarwal, CEO, Sterlite Tech, said, “We are witnessing a digital revolution globally with positive shifts in technology, national policies and consumption patterns. With developing technologies such as Cloud Computing, Augmented Reality and Internet of Things, governments globally are committed to enabling this digital revolution through national and rural broadband plans. We are facilitating this digital revolution through smarter network technologies that are the backbone of scalable broadband infrastructure.” Adding further, he said, “We are also expanding our manufacturing capacities to 50 million fkm and smarter network capabilities, in line with the global demand trends. Steve and Richard will lead this expansion into the North American and EMEA markets.”

Sterlite Tech’s optical fibre, optical fibre cable and data cables are enabling eight among top 10 telecom operators across the world with its fibre for tower, data backhaul and last-mile connectivity solutions. This is supported by the Company’s three key pillars of technology and innovation, exponential customer engagement, and strong talent and culture.

About Sterlite Technologies:

Sterlite Technologies Ltd [BSE:532374, NSE:STRTECH], is a global technology leader that designs, builds and manages smarter digital networks. Sterlite Tech engages in six continents and more than 100 countries, with a digital networks focused business panning across products, services and software – optical communication products, network and system integration services, and OSS/BSS software solutions. The Company has state-of-the-art manufacturing facilities in India, China & Brazil, and aims to transform everyday living by delivering smarter networks. With a strong portfolio of 146 patents, Sterlite Tech is home to India’s only Centre of Excellence for broadband research. Projects undertaken by the company include intrusion-proof smarter data network for the Armed Forces, rural broadband for BharatNet, Smart Cities’ development, and establishing high-speed Fibre-to-the-Home (FTTH) networks.

Visit www.sterlitetech.com.

Contact information

Sterlite Technologies Ltd
Corporate Communications
Sumedha Mahorey, +91-22-30450404
sumedha.mahorey@sterlite.com
or
Investor Relations
Vishal Aggarwal, +91-20-30514000
vishal.aggarwal@sterlite.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A18.6.2018 07:06Pressemelding

Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII) product, Nuwiq®. New single dose vial strengths of 2500, 3000 and 4000 International Units (IU) will be available in Europe, in addition to the current strengths of 250, 500, 1000 and 2000 IU. The new Nuwiq® vial strengths have been available in the US since September last year, following approval by the FDA. Nuwiq® is indicated in adults and children of all ages for on-demand treatment and prophylaxis, including during surgery, to prevent and control bleeding episodes in patients with haemophilia A. This expanded array of vial strengths has the potential to increase treatment options for patients with haemophilia A by improving dosing flexibility. Patients who previously required more than one vial per infusion may be able to reduce the number of vials needed. Nuwiq® is the only rFVIII available in an

STATS and SpokeHub Partner to Power Deeper, More Meaningful Conversations Around the 2018 FIFA World Cup18.6.2018 07:00Pressemelding

Today, STATS, the worldwide leader in sports data and intelligence, and SpokeHub announced a new partnership to bring STATS Insights to SpokeHub’s social engagement platform, connecting worldwide World Cup football (soccer) fans with content that is more impactful. Download the app today to see the match scores, player insights, and engage with World Cup fans everywhere! STATS Insights leverages more than 37 years of research experience to deliver deep historical and comparative statistical insights, play-by-play descriptions and in-game trends based on events as they happen in the match. Before, during and after each match, SpokeHub will harness STATS Insights to amplify conversations among World Cup football communities. During the game, live Insights will deliver trends on players and teams based on in-game events, statistics and milestones. “No sporting event gets global attention like the World Cup, and every fan is looking for deeper analysis around their favorite teams and playe

Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar18.6.2018 02:53Pressemelding

Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed mAb biosimilar to Herceptin® (trastuzumab). Celltrion submitted its abbreviated Biologics License Applications (aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received CRLs (complete response letters) from the FDA related to the warning letter issued by the FDA in January 2018, related to the manufacturing facility in Incheon, South Korea. Celltrion had completed the resubmission for the approval of CT-P10, a proposed biosimilar to Rituxan® (rituximab) last month. In accordance with FDA regulations, the approval procedure will be usually finalized within six months from the resubmission, so Celltrion expects the approval for the U.S. market of the two proposed biosimilars within this calendar year. FDA has notified Celltrion of its re-inspection schedule regarding regular audit results, and

CES Asia: Innovation at the Speed of 5G15.6.2018 14:59Pressemelding

CES Asia® 2018 wrapped today with the rapid pace of global innovation front and center over the show’s three day duration. The next stage of technology advancements were showcased across vehicle tech, robotics, artificial intelligence (AI), virtual and augmented reality, digital health and more. The event, 24 percent larger than last year in terms of footprint, cemented itself as the place to fully experience how the pace of technology is accelerating globally. CES Asia, the premier event for tech innovation in the Asian marketplace, will return to Shanghai, China, June 11-13, 2019. “5G and AI are igniting growth across the entire tech ecosystem changing the way we interact with technology and the world around us,” said Gary Shapiro, president and CEO, Consumer Technology Association (CTA)™. “It’s incredible to see technology refining and reinventing itself at such a fast pace. Just six months ago we were at CES with life-altering tech all around us. This week, I saw that technology re

bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association15.6.2018 10:00Pressemelding

bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy. “The maturing data from HGB-204 and HGB-207 suggest that one-time treatment with LentiGlobin may address the underlying genetic cause of TDT. With our refined manufacturing process, the majority of patients with TDT and non-β0/β0 genotypes are transfusion-free and producing total hemoglobin at normal or near-normal levels,” said David Davidson, M.D., chief medical officer, bluebird bio. “We are on track to submit a m

bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association15.6.2018 10:00Pressemelding

bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the European Hematology Association (EHA) by Julie Kanter, M.D., Medical University of South Carolina, Charleston, South Carolina. “The consistent production of increased amounts of anti-sickling HbAT87Q in the Group C patients reflects the substantial positive impact of the changes introduced with the amended HGB-206 study protocol and refined manufacturing process. All four Group C patients with greater than or equal to three months follow-up are making over 30 percent anti-sickling HbAT87Q. The first patient treated, now with six months of follow-up, is producing over 60 percent anti-sickling HbAT87Q with a normal total hemoglobin level of 14.2 g/dL,” said David Davidson, M.D., ch